Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) / National Institutes of Health (NIH). This interagency solicitation supports innovative, high-risk/high-reward research that uses convergent and interdisciplinary approaches from computer and information science, engineering, mathematical sciences, and biomedical, social, behavioral, and economic sciences to address challenges in biomedical and public health research. AI in interventional radiology fits well within this scope.

Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) and National Institutes of Health (NIH). This interagency program supports innovative, high-risk/high-reward research with the promise of disruptive transformations in biomedical and public health research. It focuses on interdisciplinary AI and data science for biomedical challenges, telehealth analytics, and remote monitoring. The work must make fundamental contributions to two or more disciplines, such as computer or information sciences, engineering, mathematical sciences, and the biomedical, social, behavioral, and economic sciences, addressing a key health problem.

NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.

NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.

Mobile Health (mHealth): Technology and Outcomes in Low and Middle Income Countries is a grant from the Fogarty International Center at NIH that funds research on mobile health technologies and their outcomes in low and middle income countries. Administered as an R21/R33 Phased Innovation Award, this funding opportunity supports studies that leverage mHealth tools to address health challenges in resource-limited settings. Participating NIH components include FIC, NEI, NIBIB, NICHD, NIDCD, NIMH, and NCI. Applications must align with the mission of the participating institutes. The program accommodates clinical trial optional designs. Award amounts vary by application and institute. The deadline for the most recent cycle was March 20, 2026.

The NIA Academic Leadership Career Award (K07, No Independent Clinical Trial) is a career development award from the National Institute on Aging (NIH) that supports established investigators who want to expand their expertise in aging-related research and academic leadership. Awards provide up to $150,000 per year to fund protected research and mentoring time. Eligible applicants are investigators with a doctoral degree (PhD, MD, or equivalent) who are named PD/PI on an active R01 or equivalent NIA grant, devote 25-50% full-time professional effort to the award, and are U.S. citizens or permanent residents. The application deadline is March 20, 2026.

Mobile Health (mHealth) is a grant from the NIH Fogarty International Center that funds exploratory and developmental research on innovative mobile health interventions and tools designed for low- and middle-income countries (LMICs). The R21/R33 program supports up to two years of technology development and feasibility studies (R21 phase), with possible transition to larger validation and effectiveness studies (R33 phase). Eligible projects must use new or emerging mobile and wireless technology; SMS-only interventions are not eligible. US institutions must involve LMIC researchers as key personnel. LMIC institutions may apply independently or with US partners. This grant is issued by Fogarty in collaboration with multiple NIH institutes including NCI, NIMH, NIBIB, and NICHD. Award amounts vary based on phase and scope.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (National Center for Complementary and Integrative Health - NCCIH) is sponsored by National Institutes of Health (NIH) / National Center for Complementary and Integrative Health (NCCIH). The NCCIH SBIR/STTR programs support innovative research conducted by small businesses or small businesses in partnership with a research institution, focusing on complementary and integrative health interventions.

NSF-NIH-FDA Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation is sponsored by National Science Foundation with NIH and FDA. The FDT-BioTech program is a joint NSF NIH and FDA initiative that catalyzes biomedical technological innovation through foundational development of methods and algorithms relevant to digital twins and synthetic humans.

The FDT-BioTech program is a joint NSF NIH and FDA initiative that catalyzes biomedical technological innovation through foundational development of methods and algorithms relevant to digital twins and synthetic humans. The program supports inherently interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications with a particular focus on digital in silico models used in the evaluation of medical devices and to advance regulatory sciences. Priority research areas include computational representations of physiological systems verification validation and uncertainty quantification transferability and generalizability across populations ethics security and privacy considerations and validation mechanisms for digital twin models. The program incorporates AI and machine learning as key enabling technologies for creating responsive digital twin models. All proposals must address regulatory science benefits and ethical implications. This program is distinct from the NSF SCH Smart Health program which focuses broadly on AI for health research and from ARPA-H programs which target specific clinical applications.

Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) is sponsored by National Science Foundation (NSF) / National Institutes of Health (NIH) / Food and Drug Administration (FDA). This program supports interdisciplinary research projects that underpin the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications, with a particular focus on digital, in silico models…

The Foundations for Digital Twins as Catalyzers of Biomedical Technological Innovation (FDT-BioTech) program is a tri-agency initiative by NSF, NIH, and FDA supporting inherently interdisciplinary research that underpins the mathematical and engineering foundations behind the development and use of digital twins and synthetic data in biomedical and healthcare applications. The program funds advances in mathematics, statistics, computational sciences, and engineering required to develop responsive digital twin models incorporating artificial intelligence capabilities. Research areas include in silico models for medical device evaluation, synthetic human generation, and emerging challenges in biomedical technology development and assessment. Awards are up to $1,000,000 for collaborative projects from multiple organizations over 3 years, with the program issuing 6 to 10 awards per cycle. The next deadline is May 4, 2026, with annual cycles on the first Monday of May thereafter. This program specifically targets the foundational computational methods that make biomedical digital twins possible rather than application-specific implementations.

Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD) / National Institutes of Health (NIH). This notice solicits grant applications seeking to improve women's health across the lifespan within the scope of NIDCD's mission. Projects may include biological, behavioral, societal, or healthcare-related activities that may benefit women's quality of life.

Notice of Special Interest (NOSI): Encouraging Women's Health Research within the NIDCD Mission Areas is sponsored by National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD). This notice solicits grant applications seeking to improve women's health across the lifespan within the scope of NIDCD's mission.

The Notice of Special Interest: Encouraging Women's Health Research within the NIDCD Mission Areas is a funding notice from NIH's National Institute on Deafness and Other Communication Disorders (NIDCD) that encourages researchers to incorporate women's health perspectives into studies of communication disorders. This notice supplements existing NIDCD grant mechanisms including R01, R15, R21, and Early Career Research awards by prioritizing research examining how hearing loss, balance disorders, voice, speech, language, and chemosensory conditions uniquely affect women. Eligible researchers include those applying to participating NIDCD programs such as PAR-21-063, PA-20-185, and PAR-21-107, which requires the PI to be within 7 years of their terminal degree. Applications were accepted through the listed parent FOA mechanisms with a September 9, 2025 due date. Award amounts vary by mechanism.

NIAID and NIDDK Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This funding opportunity encourages research project applications within the mission of either NIAID or NIDDK from New Investigators or 'At-Risk' investigators from diverse backgrounds, including those underrepresented in the health-related sciences.

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - various Institutes and Centers including NIAMS, NINDS, NCCIH. The R01 grant mechanism supports investigator-initiated research projects. Many NIH institutes, including NIAMS and NINDS, welcome pain research applications through their parent R01 announcements. This can include cellular and molecular research on pain mechanisms, CNS and PNS mechanisms of pain perception and modulation, and development of animal models of pain relevant to chronic musculoskeletal central sensitization.

Multidisciplinary Studies of HIV/AIDS and Aging is offered by the National Institutes of Health (NIH) through multiple participating institutes including NHLBI, NIAMS, NIDCR, NIDDK, NIDA, NIMH, NCI, and NIAAA. The R21 program supports innovative, exploratory research at the intersection of HIV/AIDS and aging, encouraging multidisciplinary approaches that span biomedical, behavioral, and social science. Eligible applicants include state and local governments, nonprofits, small businesses, and educational institutions. Applications are due May 7, 2026, under funding opportunity number PAR-25-355. This funding opportunity has expired but NIH may accept applications on a case-by-case basis for a short period after expiration to accommodate late or continuous submission policies.

Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01) is a grant from the National Institutes of Health (NIH/NIDA) that funds assay development, high-throughput screening, and drug discovery research targeting brain disorders including neurological and psychiatric conditions. Supported by NIMH and NIDA, the program seeks to identify and validate small molecule chemical hits that may serve as leads for new therapeutics. Eligible applicants include public and private institutions of higher education, nonprofit organizations, and small businesses engaged in drug discovery research. Awards vary based on the scope of the proposed research. The application deadline is May 7, 2026. Clinical trials are not allowed under this funding opportunity.

Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) is sponsored by National Institutes of Health (NIH), U.S. Department of Health and Human Services. Supports collaborative research to address NCD health disparities among Latin American and U. S. Hispanic/Latino populations, emphasizing innovative interventions and international partnerships.

Early Immune System Development and Ontogency (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). Supports research elucidating mechanisms of early immune development in utero, postnatal period, and early childhood, including in neonates with or without HIV/ART exposure, focusing on immune cells at maternal-fetal interface and T/B cell maturation.

Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01) is an NIH/NIDA funding opportunity that supports the development and validation of screening assays for discovering chemical hits to be used in future drug discovery efforts targeting mental illness and brain disorders. Participating organizations include the National Institute of Mental Health (NIMH). The program seeks researchers who can identify compounds with desired activity profiles that may serve as candidates for treatment of psychiatric and neurological conditions. Clinical trials are not allowed under this mechanism. Eligible applicants include public and private institutions of higher education, nonprofits, and small businesses engaged in drug discovery research. The next application deadline is May 7, 2026.

Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required) is sponsored by National Institutes of Health (NIH), U.S. Department of Health and Human Services. Supports collaborative research to address NCD health disparities among Latin American and U. S. Hispanic/Latino populations, emphasizing innovative interventions and international partnerships.

Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01) is a grant from the National Institutes of Health (NIH) that funds early-stage investigators with up to five years of support and protected time for intensive, research-focused career development using nonhuman primate research models. The program provides mentored training in biomedical research areas including allergy, infectious diseases, and research infrastructure, under the guidance of experienced mentors. The K01 mechanism supports independent clinical trial activities that are not allowed under this specific announcement. Eligible applicants include nonprofits, universities, state and local governments, and other research institutions. The application deadline is May 8, 2026.

Research Project Grants in Valvular Heart Disease (CAROL Act) is a grant from the National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute (NHLBI) that funds R01 research in valvular heart disease under the Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act. The program encourages research using advanced imaging techniques, studies on risk factors for sudden cardiac arrest from valvular heart disease, and research on mitral valve prolapse (MVP), including registry activities, data science and AI applications, basic mechanistic studies, and clinical comparative studies. Eligible applicants include private and public institutions of higher education, nonprofits, and federally recognized Native American tribal organizations. Award amounts are not specified. The deadline is May 8, 2026.

Bioengineering Research, Innovation and Technology Education (BRITE) Program is sponsored by National Institutes of Health (NIH). The BRITE program is designed to foster the development of undergraduate freshmen and sophomores to pursue further studies and careers in bioengineering, biomedical imaging, or other STEM fields relevant to NIBIB's scientific mission. It incorporates didactic, experiential, mentoring, and career development opportunities, including entrepreneurship training.

From Insight to Action: Health Equity Research that Meets This Moment is sponsored by Robert Wood Johnson Foundation and National Institutes of Health (NIH). This initiative invites community-based organizations and their research partners to apply for grants supporting action-oriented, community-centered research that demonstrates how to bring about structural changes that advance health equity.

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) is sponsored by National Center for Advancing Translational Sciences (NCATS) at NIH. This NIH grant supports research to advance clinical trial readiness for rare diseases, disorders, and syndromes. Given that argininosuccinic aciduria is a rare genetic disorder where current treatments are often unsatisfactory, research focused on developing gene therapy to prepare for clinical trials would be highly relevant.

National Institutes of Health (NIH) Collaborative International Research Project (Parent PF5 Clinical Trial Optional) is sponsored by U.S. Department of Health and Human Services; National Institutes of Health (NIH). This NIH program supports international biomedical research collaborations between U.S. and foreign organizations, emphasizing joint scientific projects. It is a broad program that could encompass integrative health research in Brazil and Latin America.

Limited Competition: National Primate Research Centers (P51) is a grant from the National Institutes of Health (NIH), administered through the Division of Program Coordination, Planning, and Strategic Initiatives (ORIP), that funds the operation of National Primate Research Centers providing shared research infrastructure and nonhuman primate models for biomedical research. This is a limited competition open only to existing center grantees and does not allow clinical trials. The funding opportunity has been updated to align with current agency priorities. Eligible applicants include universities, nonprofits, state and local governments, and foreign institutions meeting the limited competition criteria. The application deadline is May 25, 2026.